Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal CancerScott Kopetz, Josep Tabernero, Jayesh Desai et al.|New England Journal of Medicine|2019Cited by 1.5k
TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in <i>KRAS</i>-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancerLine Schmidt Tarpgaard, José M.A. Moreira|Oncotarget|2016Cited by 9